SG194453A1 - Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset - Google Patents
Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset Download PDFInfo
- Publication number
- SG194453A1 SG194453A1 SG2013075668A SG2013075668A SG194453A1 SG 194453 A1 SG194453 A1 SG 194453A1 SG 2013075668 A SG2013075668 A SG 2013075668A SG 2013075668 A SG2013075668 A SG 2013075668A SG 194453 A1 SG194453 A1 SG 194453A1
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- cancer
- motesanib
- small cell
- cell lung
- Prior art date
Links
- 229950003968 motesanib Drugs 0.000 title abstract 2
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 title abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title 2
- 229940123237 Taxane Drugs 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940041181 antineoplastic drug Drugs 0.000 title 1
- 229910052697 platinum Inorganic materials 0.000 title 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000004083 survival effect Effects 0.000 abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides a method of improving survival associated with cancer in a subset of the general population. The invention provides a method of improving survival associated with cancer in patients of Asian ethnic background. In addition, the present application relates to the treatment of angiogenesis related disease in an Asian patient with kinase inhibitors. In addition the present application relates to the treatment of non-small cell lung cancer in an Asian patient with motesanib.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161475163P | 2011-04-13 | 2011-04-13 | |
| PCT/US2012/033376 WO2012142325A1 (en) | 2011-04-13 | 2012-04-12 | Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG194453A1 true SG194453A1 (en) | 2013-12-30 |
Family
ID=46018098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013075668A SG194453A1 (en) | 2011-04-13 | 2012-04-12 | Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JP2014510793A (en) |
| KR (1) | KR20140022876A (en) |
| CN (1) | CN103764139A (en) |
| AU (1) | AU2012242773A1 (en) |
| PH (1) | PH12013502129A1 (en) |
| SG (1) | SG194453A1 (en) |
| TW (1) | TW201304777A (en) |
| WO (1) | WO2012142325A1 (en) |
-
2012
- 2012-04-12 PH PH1/2013/502129A patent/PH12013502129A1/en unknown
- 2012-04-12 JP JP2014505293A patent/JP2014510793A/en active Pending
- 2012-04-12 CN CN201280029079.XA patent/CN103764139A/en active Pending
- 2012-04-12 WO PCT/US2012/033376 patent/WO2012142325A1/en not_active Ceased
- 2012-04-12 SG SG2013075668A patent/SG194453A1/en unknown
- 2012-04-12 AU AU2012242773A patent/AU2012242773A1/en not_active Abandoned
- 2012-04-12 KR KR1020137029658A patent/KR20140022876A/en not_active Withdrawn
- 2012-04-13 TW TW101113329A patent/TW201304777A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140022876A (en) | 2014-02-25 |
| PH12013502129A1 (en) | 2014-01-06 |
| TW201304777A (en) | 2013-02-01 |
| AU2012242773A1 (en) | 2013-05-02 |
| CN103764139A (en) | 2014-04-30 |
| JP2014510793A (en) | 2014-05-01 |
| WO2012142325A1 (en) | 2012-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ602385A (en) | Methods of treating cancer | |
| PH12014501880A1 (en) | Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy | |
| MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
| MX2015008114A (en) | Exendin-4 Derivatives. | |
| NZ716473A (en) | Diagnosis and therapy of cancer involving cancer stem cells | |
| MX372883B (en) | USE OF ANTIBODIES AGAINST CLAUDIN 18.2 FOR THE TREATMENT OF CANCER. | |
| TN2015000091A1 (en) | Glucosylceramide synthase inhibitors | |
| MX365365B (en) | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy. | |
| EA201391114A1 (en) | METHODS OF USE ALK-INHIBITORS | |
| MX2012007898A (en) | Methods of providing weight loss therapy in patients with major depression. | |
| CL2013003324A1 (en) | Composition comprising chemotherapy with paclitaxel and carboplatin and an anti-clusterine oligonucleotide; use of the composition for the treatment of a human patient suffering from lung cancer. | |
| MY176219A (en) | Combination therapy for cancer | |
| NZ701553A (en) | Medicine comprising combination of general anesthetic drug and hydrogen | |
| WO2012082821A3 (en) | Melanoma treatments | |
| WO2012109233A3 (en) | Methods for predicting recurrence risk in breast cancer patients | |
| MX2015015601A (en) | Method of treating lung cancer by vaccination with muc-1 lipopeptide. | |
| SG10201908587PA (en) | Treatment regimens | |
| BR112013019080A2 (en) | methods for treating cancer, nsclc and colorectal cancer in a human patient and article of manufacture | |
| PH12015502516A1 (en) | Efficacious treatment of nsclc and predictive clinical marker of the responsiveness of a tumour to a treatment | |
| SG194453A1 (en) | Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset | |
| EP2879712A4 (en) | Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug | |
| HK1218939A1 (en) | Drug selection for non-small cell lung cancer therapy | |
| MX2015004940A (en) | Treatment of depression and ptsd. | |
| PH12014502464A1 (en) | Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases | |
| UA73001U (en) | method for treating patients with pulmonary tuberculosis combined with HIV/AIDS |